Compared to adult studies, the safety and efficacy endpoints may need to be adjusted such that safety follow-up is adequate in terms of length and specificity to detect adverse effects after completion of the study and as children develop and grow.
Esto con el fin de poder detectar los efectos adversos una vez terminado el estudio y durante el crecimiento y desarrollo de los niños.